Intermittent fasting shows promise in slowing Huntington’s disease progression
Peer-Reviewed Publication
Updates every hour. Last Updated: 31-Oct-2026 07:15 ET (31-Oct-2026 11:15 GMT/UTC)
A simple change in when people eat may offer a promising new approach for Huntington’s disease, according to research led by Oregon Health & Science University.
In a 12-week pilot study, researchers found that people with early-stage Huntington’s disease were able to safely follow a form of intermittent fasting known as time-restricted eating, limiting food consumption to a six-to-eight-hour window each day. Participants avoided unintended weight loss and showed improvements in measures of disease severity; in a blood biomarker linked to nerve cell damage; and in cellular energy production.
As climate change drives more frequent and intense wildfires, researchers at the Icahn School of Medicine at Mount Sinai have published two large-scale studies showing that wildfire smoke may pose greater health risks than other sources of air pollution, with higher risks of hospitalization for cardiovascular and respiratory disease and poorer survival among patients with lung cancer.
Researchers have developed an orally administered chirality-engineered nanozyme that protects the heart from chemotherapy-induced damage by targeting the gut rather than the heart itself. The nanozyme reshapes gut microbiota and host metabolism through the gut-heart axis, significantly alleviating doxorubicin-induced cardiotoxicity while preserving the anticancer efficacy of doxorubicin. The study highlights stereochemical engineering as a promising strategy for designing next-generation nanozyme therapeutics.
Combining large-scale genetic data with single-cell analysis, the team pinpoints the key cells and genes driving psoriasis